

NATIONAL INSTITUTE FOR HEALTH AND CARE EXCELLENCE

Single Technology Appraisal

Alectinib for adjuvant treatment of ALK-positive non-small-cell lung cancer ID6368

Provisional Stakeholder List

| Consultees | Commentators (no right to submit or |
|--|---|
| | appeal) |
| Company | General |
| Roche (alectinib) | All Wales Therapeutics and Toxicology Centre |
| Patient/carer groups | Allied Health Professionals Federation |
| ALK Positive UK | Board of Community Health Councils in |
| Asthma and Lung UK | Wales |
| Black Health Agency for Equality | British National Formulary |
| Cancer Black Care | Care Quality Commission |
| Cancer Equality | Department of Health, Social Services |
| Cancer52 | and Public Safety for Northern Ireland |
| Helen Rollason Cancer Charity | Healthcare Improvement Scotland Madiainage and Healthcare products |
| Independent Cancer Patients Voice | Medicines and Healthcare products Populatory Agoney |
| Macmillan Cancer Support | Regulatory AgencyNational Association of Primary Care |
| Maggie's Centres Marie Curie | National Association of Finnary Care National Pharmacy Association |
| _ | NHS Confederation |
| Oncogene-Driven Lung Cancer Patient Alliance | Scottish Medicines Consortium |
| Roy Castle Lung Cancer Foundation | Welsh Government |
| Ruth Strauss Foundation | Welsh Health Specialised Services |
| South Asian Health Foundation | Committee |
| Specialised Healthcare Alliance | |
| Tenovus Cancer Care | Possible comparator companies |
| UK Lung Cancer Coalition | Aspire Pharma (pemetrexed) |
| | Bristol Myers Squibb (paclitaxel) |
| Healthcare professional groups | • Dr Reddy's Laboratories (pemetrexed) |
| Association of Cancer Physicians | Eli Lilly (pemetrexed) |
| Association of Respiratory Nurse | Genus Pharmaceuticals (pemetrexed) |
| Specialists | Medac (oxaliplatin) |
| British Geriatrics Society | Merck Sharp & Dohme UK |
| British Institute of Radiology | (pembrolizumab) |
| British Oncology Pharmacy | • Pfizer (cisplatin, carboplatin, docetaxel, |
| Association | oxaliplatin, paclitaxel, pemetrexed) |
| British Psychosocial Oncology Society | Ranbaxy (oxaliplatin) |
| British Thoracic Oncology Group | Roche (atezolizumab) |
| British Thoracic Society | Sandoz (cisplatin, pemetrexed) |
| Cancer Research UK | |

Provisional stakeholder list for the evaluation of alectinib for adjuvant treatment of ALK-positive nonsmall-cell lung cancer ID6368

Issue date: January 2024

© National Institute for Health and Care Excellence 2024. All rights reserved.

| Consultees | Commentators (no right to submit or appeal) |
|--|--|
| Lung Cancer and Mesothelioma Clinical Expert Group Lung Cancer Nursing UK National Heart and Lung Institute Primary Care Respiratory Society UK Royal College of General Practitioners Royal College of Nursing Royal College of Pathologists Royal College of Physicians Royal College of Radiologists Royal College of Radiologists Royal Pharmaceutical Society Royal Society of Medicine Society and College of Radiographers UK Clinical Pharmacy Association UK Oncology Nursing Society | appeal) Seacross Pharmaceuticals (paclitaxel, oxaliplatin, docetaxel) Teva UK (paclitaxel) Zentiva (pemetrexed) Relevant research groups British Association of Lung Research Cochrane Airways Group Cochrane Lung Cancer Group Genomics England Institute of Cancer Research MRC Clinical Trials Unit National Institute for Health Research Associated Public Health groups Public Health Wales |
| Others | UK Health Security Agency |
| Department of Health and Social CareNHS England | |

NICE is committed to promoting equality, eliminating unlawful discrimination and fostering good relations between people who share a protected characteristic and those who do not. Please let us know if we have missed any important organisations from the stakeholder list, and which organisations we should include that have a particular focus on relevant equality issues.

Definitions:


Consultees

Organisations that accept an invitation to participate in the evaluation; the company that markets the technology; national professional organisations; national patient organisations; the Department of Health and Social Care and relevant NHS organisations in England.

The company that markets the technology is invited to make an evidence submission, respond to consultations, nominate clinical experts and has the right to appeal against the Final Draft Guidance (FDG).

All non-company consultees are invited to submit a statement relevant to the group they are representing, respond to consultations, nominate clinical or patient experts and have the right to appeal against the Final Draft Guidance (FDG).

Commentators



Organisations that engage in the evaluation process but that are not asked to prepare an evidence submission or statement, are able to respond to consultations and they receive the FDG for information only, without right of appeal. These organisations are: companies that market comparator technologies; Healthcare Improvement Scotland; related research groups where appropriate (for example, the Medical Research Council [MRC]); other groups (for example, the NHS Confederation and the British National Formulary).

All non-company commentators are invited to nominate clinical or patient experts.